Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials Closed to Accrual

Canadian Cancer Trials Group IND.211 - A Randomized Phase II Study of Reolysin in Patients with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Receiving Standard Salvage Therapy - was closed to accrual on August 6, 2015 after reaching its accrual goal.

Canadian Cancer Trials Group MAC.14 (ECOG ACRIN E2108) - A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer was closed to accrual on July 23, 2015 after reaching its accrual goal. Six Canadian sites were activated, with 12 patients registered and 8 patients randomized.

Thanks go to all participating centres, staff and patients for their contributions to these trials.